Rutgers Cancer Institute names new chief of bone marrow transplant and cellular therapies
Click Here to Manage Email Alerts
Ira Braunschweig, MD, has been appointed as section chief of transplant and cell therapy at Rutgers Cancer Institute of New Jersey.
Braunschweig will also serve as chief of the Transplant and Cell Therapy Service of the RWJBarnabas Health Oncology Service Line, and director for cell therapy and bone marrow transplantation at Robert Wood Johnson University Hospital.
The appointments will take effect June 1.
Braunschweig is a graduate of New York University School of Medicine and completed his residency in internal medicine at Memorial Sloan Kettering Cancer Center. He served as a fellow in hematology/oncology at The University of Texas MD Anderson Cancer Center, where he subsequently became a member of the faculty and the institution’s Blood and Marrow Transplant Program.
He previously served as director of the Stem Cell Transplant Program and director of hematologic malignances at Montefiore Einstein Cancer Center. There he developed a stem cell transplant program recognized for its quality by the Foundation for the Accreditation of Cellular Therapy.
“Dr. Braunschweig is a proven leader in the growth of blood and marrow transplant programs and will utilize his expertise in the field and his innovation to elevate the stature of and expand our Blood and Marrow Transplant and Cellular Therapies Program, statewide,” Steven K. Libutti, MD, FACS, director of Rutgers Cancer Institute and senior vice president of oncology services at RWJBarnabas Health, said in a press release.
Braunschweig will oversee the clinical and research activities of the Blood and Marrow Transplant and Cellular Therapies Program at Rutgers Cancer Institute as part of his new duties. The program is a collaboration with Robert Wood Johnson University Hospital and offers both autologous and allogeneic hematopoietic stem cell transplants for patients with hematologic malignancies.
“I feel fortunate to begin working with such a skilled and passionate team of specialists at New Jersey’s only National Cancer Institute-designated comprehensive cancer center,” Braunschweig said in the release. “Together we will continue to build on a strong foundation of excellence in blood and bone marrow transplantation and cell therapy research and clinical practice.”